Lunai Bioworks Inc. · NASDAQ:LNAI
Lunai Bioworks — Enochian Biosciences — Innate Killer Summit 2023
10 slides from Lunai Bioworks's conference presentation, Mar 28, 2023
Slide 1: Discussing Mechanisms of Inhibition by Myeloid Compartment
Enochian Biosciences’ Related Excerpt of Full Presentation Discussing Mechanisms of Inhibition by Myeloid Compartment Innate Killer Summit San Diego, CA March 28, 2023 by Dr. Anahid Jewett, Professor, UCLA
Slide 2: Cutting Edge Personalized Cancer Therapy
. <= Cutting Edge a Personalized Cancer Therapy Enochian (9) Ship frozen Cancer Antigen, Tumor resection pulse/uptake ao | Biopsy cme ee crete Thaw and into mature Inject engineered Engineered monocyte CD14+ = differentiation Mobilized into immature engineered Leukopak 2 dendritic cells cD34+ recove
Slide 3: Flow Cytometry Panel for Assessment of ENOB-DC11
Flow Cytometry Panel for Assessment of ENOB-DC11 Marker HSC Monocyte im-DC m-DC Marker for Function CD34 + - - - HSC Surface glycoprotein and functions as a cell-cell adhesion factor CD14 - + - - monocyte An anchor protein, a ubiquitous pattern recognition receptor specific for ligands CD209 - - + l
Slide 4: ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Reduces Tumor Size
ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Reduces Tumor Size Tumor weight Tumor volume 0.8 2500 Tumor weight (grams) ***p= 0.0001 Tumor volume (mm3) ***p= 0.0006 0.6 2000 *p= 0.01 n= 4 **p= 0.001 n=4 1500 0.4 n= 4 ***p=0.000 1000 3 0.2 n= 500 4 n= n=1 6 n= 0.0 0 6 No
Slide 5: ENOB-DC11 Significantly Increases the Percentages of CD8+ T cells in Peripheral Blood
ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Increases the Percentages of CD8+ T cells in Peripheral Blood N=2-3
Slide 6: ENOB-DC11 Significantly Increases the Percentages of T and B Cells in Spleen
ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Increases the Percentages of T and B Cells in Spleen N=2-3
Slide 7: ENOB-DC11 Significantly Increases the Percentages of NK and T Cells in Bone Marrow
ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Increases the Percentages of NK and T Cells in Bone Marrow N=2-3
Slide 8: ENOB-DC11 Significantly Increases the IL-2 Mediated Lysis of OSCSCs by NK Cells
ENOB-DC11 Treatment of Pancreatic Tumor-Bearing Hu-BLT Mice Significantly Increases the IL-2 Mediated Lysis of OSCSCs by the NK Cells Within PBMCs; Anti-CD16mAb Blocks NK Cell Mediated Lysis N=2-3
Slide 9: ENOB-DC11 Significantly Increases IFN-g Secretion by Splenocytes
ENOB-DC11 Treatment of Pancreatic Tumor-bearing Hu-BLT Mice Significantly Increases IFN-g Secretion by Splenocytes BLT26 Spleen ELISA 2d treatment BLT26 Spleen ELISA 6d treatment N=2-3
Slide 10: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain statements in this presentation that are not strictly historical in nature, regarding our future operations, strategy, potential regulatory treatment, acceptance or changes, preclinical opportunities or activities, potential commercial sales, or outcomes of later c